/
Other
MODY
1
Pipeline Programs↗
1
Active Trials↗
0
Companies Involved↗
MODY is an early-stage landscape with 1 program across 0 companies. The most active players are Chong Kun Dang Pharmaceutical.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
8
clinical trials
Unknown status4 · 50%
Completed2 · 25%
Terminated1 · 13%
Recruiting1 · 13%
Clinical Trials
Trial Activity
8 trials
Pharmacodynamic Analysis of the HaemOdynamic Effects of a Standard Fluid BolUS
Recruiting·—·N/A·NCT06839404·500 enrolled
Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters
Unknown status·—·N/A·NCT02490176·50 enrolled
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin
Unknown status·—·Phase 2·NCT03449251·170 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)